Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copper-64 DOTATATE - Curium/RadioMedix

Drug Profile

Copper-64 DOTATATE - Curium/RadioMedix

Alternative Names: 64-Cu-DOTA-TATE; 64-Cu-Dotatate; Netmedix

Latest Information Update: 11 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RadioMedix
  • Class Imaging agents; Organometallic compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuroendocrine tumours

Most Recent Events

  • 09 Jan 2019 Copper-64 DOTATATE receives Fast Track designation for Neuroendocrine tumours [Parenteral] (Diagnosis) in USA
  • 09 Jan 2019 RadioMedix announces intention to launch copper-64 DOTATATE for Neuroendocrine tumours (Diagnosis) in USA
  • 09 Jan 2019 RadioMedix completes a phase III trial in Neuroendocrine tumours (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top